Suggestions
Thierry Van Nieuwenhove, CFA
Founding Partner - VGL Fusões & Aquisições
Thierry Van Nieuwenhove is a seasoned professional in the pharmaceutical and financial sectors, currently serving as the Chief Executive Officer (CEO) of Quotient Sciences, a role he assumed on October 16, 2023. With over 23 years of experience in the pharma/CDMO (Contract Development and Manufacturing Organization) industry, he has held various senior leadership positions, including CEO at ABL Inc., President of the Synthesis business unit at Novasep, and Global Head of Business Development at Lonza.12
In addition to his recent appointment at Quotient Sciences, Van Nieuwenhove is also a Founding Partner at VGL - Fusões & Aquisições, a mergers and acquisitions firm based in São Paulo, Brazil. His background includes seven years in equity research and corporate finance at BankBoston, where he was involved in financial advisory services.35
Van Nieuwenhove holds the CFA (Chartered Financial Analyst) designation, reflecting his expertise in finance and investment management. His educational background and diverse experience across various organizations have equipped him with a profound understanding of global pharmaceutical pipelines and outsourcing strategies.4
He is recognized for his leadership capabilities and commitment to advancing drug development processes to improve patient outcomes globally.2
